T. Andrew Crockett

2019

In 2019, T. Andrew Crockett earned a total compensation of $3.3M as Chief Executive Officer at Carbylan Therapeutics, a 61% increase compared to previous year.

Compensation breakdown

Bonus$353,500
Option Awards$2,418,444
Salary$505,000
Other$11,000
Total$3,287,944

Crockett received $2.4M in option awards, accounting for 74% of the total pay in 2019.

Crockett also received $353.5K in bonus, $505K in salary and $11K in other compensation.

Rankings

In 2019, T. Andrew Crockett's compensation ranked 3,711th out of 13,971 executives tracked by ExecPay. In other words, Crockett earned more than 73.4% of executives.

ClassificationRankingPercentile
All
3,711
out of 13,971
73rd
Division
Manufacturing
1,339
out of 5,701
77th
Major group
Chemicals And Allied Products
465
out of 2,200
79th
Industry group
Drugs
390
out of 1,886
79th
Industry
Pharmaceutical Preparations
294
out of 1,398
79th
Source: SEC filing on August 23, 2019.

Crockett's colleagues

We found three more compensation records of executives who worked with T. Andrew Crockett at Carbylan Therapeutics in 2019.

2019

Benjamin Palleiko

Carbylan Therapeutics

Chief Financial Officer

2019

Edward Feener

Carbylan Therapeutics

Chief Scientific Officer

2019

Christopher Yea

Carbylan Therapeutics

Chief Development Officer

News

In-depth

You may also like